The chatbot will see you now:

Use of automation in the informed consent process for genomics research studies leads to wider reach and better understanding

2023-06-13

(Press-News.org) Glasgow, UK: The informed consent process in biomedical research is biased towards people who can meet with clinical study staff during the working day. For those who have the availability to have a consent conversation, the time burden can be off-putting. Professor Eric Vilain, from the Department of Paediatrics, University of California, Irvine, USA, will tell the European Society of Human Genetics annual conference today (Tuesday 13 June) how results from his team’s study of the use of a chatbot (GIA – ‘Genetics Information Assistant’ developed by Invitae Corporation) in the consent process show that it encourages inclusivity, and leads to faster completion and high levels of understanding. Since such consent is the cornerstone of all research studies, finding ways of cutting the time spent on it while continuing to make sure that participants’ understanding is not lessened is something clinicians have aimed for some time.

Working with their institutional review board (IRB), Prof Vilain’s team from across University of California Irvine, Children’s National Hospital, and Invitae Corporation designed a script for the GIA chatbot to transform the trial consent form and protocol into a logic flow and script. Unlike conventional methods of obtaining consent, the bot was able to quiz participants to assess the knowledge they had attained. It could also be accessed at any time, allowing individuals with less free time to use it outside normal business hours. “We saw that more than half of our participants interacted with the bot at these times, and this shows its utility in decreasing the barriers to entry to research. Currently, most people who participate in biomedical research have time to do so as well as the knowledge that studies exist,” says Prof Vilain

The researchers involved 72 families in the consent process during a six-month time period as part of the US national GREGoR consortium, a National Institutes of Health initiative to advance rare disease research. A total of 37 families completed consent using the traditional process, while 35 used the chatbot. The researchers found that the median length of the consent conversation was shorter for those using the bot, at 44 rather than 76 minutes, and the time from referral to the study to consent completion was also faster, at five as opposed to 16 days. The level of understanding of those who had used the bot was assessed with a 10-question quiz that 96% of participants passed, and a request for feedback showed that 86% thought that they had had a positive experience.

“I was surprised and pleased that a significant number of people would feel comfortable communicating with a chatbot,” says Prof Vilain. “But we worked hard with our IRB to ensure that it didn’t ‘hallucinate’ (make mistakes) and to ensure that knowledge was conveyed correctly. When the bot was unable to answer a question, it encouraged the participant to speak with a member of the study team.”

While it is not possible to give an accurate account of cost saving, the time savings of staff were substantial, the researchers say. Because people can pause the chatbot consent process at any time, it can be completed much more quickly – for example, four participants completed in 24 hours. Of the consent conversations that were quick (less than an hour), 83% of them were with the chatbot. The consent conversations that were longer (between one and two hours), were with a study staff member (66%).

“But it’s far from being just about speed,” says Prof Vilain. “The traditional method of consenting does not have a mechanism to verify understanding objectively. It is based on the conviction of the study staff member hosting the conversation that the consent has been informed properly and the individual understands what they are consenting to. The chat-based method can test comprehension more objectively. It does not allow users who do not show understanding to give consent, and puts them in touch with a genetic counsellor to figure out why knowledge transmission did not occur.

“We believe that our work has made an important contribution to the obtention of properly-informed consent, and would now like to see it used in different languages to reach global populations,” he concludes.

Professor Alexandre Reymond, chair of the conference, said: “The keystone to informed consent should be that it is by definition ‘informed’, and we should explore all possibilities to ensure this in the future.”

(ends)

Abstract no. C28.3: Development and Implementation of Novel Chatbot-based Genomic Research Consent

END

ELSE PRESS RELEASES FROM THIS DATE:

NHS policies on patient’s weight and access to hip replacement surgery are inappropriate, study finds

2023-06-13

Weight and body mass index (BMI) policies introduced by NHS commissioning groups in England are inappropriate and worsening health inequalities, according to a new study published in BMC Medicine today [13 June] that analysed nearly 490,000 hip surgeries. With one in ten people likely to need a joint replacement in their lifetime, many thousands of patients are directly affected by these policies. Rules implemented by NHS clinical commissioning groups (CCGs) across England to change the access to hip and knee replacement surgery for patients who are overweight or obese have been in effect for over ten years. ...

A baking soda solution for clean hydrogen storage

2023-06-13

In a world of continuously warmer temperatures, a growing consensus demands that energy sources have zero, or next-to-zero, carbon emissions. That means growing beyond coal, oil, and natural gas by getting more energy from renewable sources. One of the most promising renewable energy carriers is clean hydrogen, which is produced without fossil fuels. It’s a promising idea because the most abundant element in the universe is hydrogen, found in 75 percent of all matter. Moreover, a hydrogen molecule has two paired atoms—Gemini twins that are both non-toxic and highly combustible. Hydrogen’s combustive potential ...

Can this medication reverse MS? Brain biomarker shows it can

2023-06-13

A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug’s effectiveness in repairing the brain, making it possible to also assess future therapies for the devastating disorder. The researchers, led by physician-scientist Ari Green, MD, who together with neuroscientist Jonah Chan, PhD, first identified clemastine as a potential MS therapy, used MRI scans to study the drug’s impact on the brain of 50 participants in a clinical study. In MS, patients lose myelin, the protective insulation around ...

The advances and promise of continuous glucose monitoring in diabetes management

2023-06-13

As adoption of Continuous Glucose Monitoring (CGM) continues to increase, there is a growing body of evidence supporting the use of this technology in improving diabetes outcomes for patients with Type 1 or Type 2 Diabetes. A new supplement in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) provides an excellent perspective of the past, present, and future of CGM. Click here to read the supplement now. In the supplement Rickson et al. review the rapid pace in which diabetes technology has progressed and the implications for relying on rigorous and extensive timelines to publish randomized controlled trials to impact ...

Ochsner Health names new chief financial officer and treasurer

2023-06-13

NEW ORLEANS, La. – Ochsner Health has named Jim Molloy as the organization’s next Executive Vice President, Chief Financial Officer and Treasurer. A leader at Citi bringing decades of extensive experience in healthcare finance, Molloy will oversee the organization’s accounting, financial planning and analysis, reimbursement and revenue cycle functions, as well as managed care contracting and treasury. He will also play a pivotal role in the continued development and execution of ...

Low birthweight is independently linked to increased risk of type 2 diabetes, and a particular presentation including lower age at diagnosis

2023-06-13

T2D patients with lower birthweight also show higher use of diabetes drugs than those with normal birthweight, and a larger number of comorbidities including high blood pressure, at the time of diagnosis. The first study is by Dr Rasmus Wibaek, Steno Diabetes Center Copenhagen, Herlev, Denmark, and Dr Allan Vaag, Steno Diabetes Center Copenhagen, and also Lund University, Malmö, Sweden, and colleagues. This study included adults aged 30–60 years enrolled in the Danish Inter99 cohort in 1999–2001 (baseline examination), with information on birthweight from original birth records from 1939–1971 and without diabetes at baseline. Birth records were linked ...

Gentle cleansers kill viruses as effectively as harsh soaps, study finds

2023-06-13

Gentle cleansers are just as effective in killing viruses – including coronavirus – as harsh soaps, according to a new study from scientists at the University of Sheffield Healthcare professionals often substitute alcohol-based hand sanitisers and harsh soaps for skin-friendly cleansers in order to treat or prevent irritant contact dermatitis, which develops when chemical or physical agents damage the skin surface faster than the skin can repair Incidence and severity of irritant contact dermatitis increased from 20 per cent to 80 per cent amongst healthcare professionals during the Covid-19 pandemic Researchers also found non-enveloped ...

LP-284 targets non-Hodgkin's lymphoma and DNA damage repair deficiency

2023-06-12

“[...] we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.” BUFFALO, NY- June 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” Despite advances in therapies treating non-Hodgkin’s ...

Damon Runyon Cancer Research Foundation announces three recipients of 2023 Physician-Scientist Training Award

2023-06-12

Three scientists with exceptional promise and novel approaches to fighting cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award. The awardees were selected through a highly competitive and rigorous process by a scientific committee comprised of leading cancer researchers who are themselves physician-scientists. Physician-scientists are uniquely positioned to translate scientific discoveries into therapies that improve and prolong the lives of their patients. However, ...

Where there’s smoke are lessons in demands of global sustainability

2023-06-12

As the world struggles for sustainability in the face of climate change, wildfire smoke becomes a lesson in how people can become victims far from the root of a problem and far from their control. In this month’s open access National Science Review, Jianguo “Jack” Liu, MSU Rachel Carson Chair in Sustainability, makes a case for the world to shake off the constraints of traditional governance, which tends to address issues in one place without considering how people or ecologies near and far might be impacted. Justice at a global scale can be threatened when natural events or human decisions in one part of the world to protect, reroute, ...

LAST 30 PRESS RELEASES:

Advances in endovascular therapy for stroke patients

The Lancet Public Health: MMR vaccine remains the best protection against measles - modelling study in England suggests level of protection decreases slightly over time